Lianhua Pharmaceutical (600513.SH): Clinical trial of Riluzole tablets approved.

Zhitong Finance APP News, LianHuan Pharmaceutical (600513.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration regarding the approval of Rulogoli tablets. The company has officially obtained approval to conduct clinical trials for Rulogoli tablets for the treatment of prostate cancer, and will soon initiate a Phase III multicenter clinical trial to evaluate the efficacy and safety of Rulogoli tablets in treating hormone-sensitive advanced prostate cancer.